Skip to main content

Table 1 Currently proven treatment options for mCRPC patients in the post-docetaxel space [9, 10]

From: Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space

Drug (trial) Class (comparator) Primary outcomes vs comparator (hazard ratio [HR]) 95% CIs P value
Abiraterone acetate + prednisone (COU-AA-301) Antiandrogen
(prednisone/placebo)
Median OS = 14.8 vs 10.9 mo
(HR = 0.65)
0.54-0.77 < 0.0001
   Median TTPP = 10.2 vs 6.6 mo
(HR = 0.58)
0.46-0.73 < 0.0001
   Median rPFS = 5.6 vs 3.6 mo
(HR = 0.67)
0.58-0.78 < 0.0001
   PSA response: 38% vs 10% - < 0.0001
Cabazitaxel + prednisone (TROPIC) Chemotherapy (mitoxantrone/pred-nisone) Median OS = 15.1 vs 12.7 mo
(HR = 0.70)
0.59-0.83 < 0.0001
   Median PFS = 2.8 vs 1.4 mo
(HR = 0.74)
0.64-0.86 < 0.0001
   Tumor response = 14.4% vs 4.4% - 0.0005
   PSA response = 39.2% vs 17.8% - 0.0002
  1. CIs: confidence intervals; mCRPC: metastatic castrate-resistant prostate cancer; mo: months; OS: overall survival; PFS: progression-free survival; PSA: prostate-specific antigen; rPFS: radiologic PFS; TTPP: time to pain progression.